Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00179920|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : August 5, 2020
Retinoblastoma is an unusual cancer of early childhood involving tumor is both eyes or, in certain circumstances, one eye only. This condition is the result of an abnormal gene which makes both retinas (the back of the eye) vulnerable to develop multiple tumors. Growths in the eye impair vision temporarily or permanently. These tumors are malignant, which means that they can grow within the eye, spread outside of the eye, and be fatal if untreated.
Standard therapy for bilateral retinoblastoma includes removal of one eye if vision cannot be save and radiation treatment of either eye in which vision might be saved. Radiation controls tumor growth in the majority of cases. Another standard method is cryotherapy (freezing a tumor to kill it). Chemotherapy (medicines used to kill tumor cells) has been used in the past for tumor in or outside the eye, but is not standard. Hyperthermia, increasing the temperature of a tumor to kill it, is widely performed, and can be done to a retinoblastoma tumor by a laser; this method is not standard.
The problem with removal of an eye is that any hope of vision is lost. The problems with radiation include incomplete control of tumor, injury to the eye or surrounding tissue with decreased growth, and that (due to the abnormal retinoblastoma gene) children are very susceptible to develop other tumors, especially in the tissue which was given radiation.
The doctors at Children's Memorial Hospital are using a newer form of treatment, including laser hyperthermia, chemotherapy and cryotherapy to decrease retinoblastoma tumors. Some may be controlled indefinitely, reducing the number of eyes that need radiation or removal.
- To find out how well chemotherapy plus cryotherapy and laser hyperthermia work on retinoblastoma tumors.
- To find out whether vision can be saved and tumors controlled without radiation or removal of the eye.
|Condition or disease||Intervention/treatment||Phase|
|Retinoblastoma Retinal Neoplasms||Drug: Carboplatin Drug: VP-16 Procedure: Local Surgery Procedure: Cryotherapy Procedure: Laser hyperthermia||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Chemotherapy Plus Local Surgical Treatment in Children With Intraocular Germ-Line Retinoblastoma|
|Study Start Date :||April 1996|
|Study Completion Date :||September 2006|
- To determine if a multimodal approach can provide durable control of retinoblastoma and specifically:
- Estimate the proportion of eyes in which radiation therapy can be omitted
- Estimate the proportion of eyes in which vision can be retained
- To estimate the response rate and duration for primary retinoblastoma tumors to combination therapy with carboplatin and VP-16
- To estimate the response rate of qualifying in situ retinoblastoma tumors to local surgical therapies, specifically estimate tumor response and duration after laser hyperthermia concurrent with carboplatin
- Estimate tumor response and duration after cryotherapy
- To estimate the control rate of vitreous involvement by retinoblastoma to carboplatin and VP-16
- To detect any toxicities resulting from multimodal therapy plus local surgical options
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00179920
|United States, Illinois|
|Children's Memorial Hospital|
|Chicago, Illinois, United States, 60614|
|Principal Investigator:||Stewart Goldman, MD||Ann & Robert H Lurie Children's Hospital of Chicago|